Financials (USD)
Sales 2024 * | 240M | Sales 2025 * | 299M | Capitalization | 2.34B |
---|---|---|---|---|---|
Net income 2024 * | 5M | Net income 2025 * | 24M | EV / Sales 2024 * | 9.73 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 7.81 x |
P/E ratio 2024 * |
454
x | P/E ratio 2025 * |
102
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.06% |
Latest transcript on Aastrom Biosciences Inc
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 60 | 13-02-28 | |
Joseph Mara
DFI | Director of Finance/CFO | 49 | 21-01-24 |
Michael Halpin
COO | Chief Operating Officer | 62 | 17-04-09 |
Members of the board | Title | Age | Since |
---|---|---|---|
Paul Wotton
BRD | Director/Board Member | 63 | 15-01-05 |
Kevin McLaughlin
BRD | Director/Board Member | 67 | 15-01-05 |
Robert Zerbe
CHM | Chairman | 73 | 06-01-15 |
1st Jan change | Capi. | |
---|---|---|
-2.61% | 88.47B | |
+3.55% | 40.71B | |
-14.40% | 32.43B | |
+55.89% | 24.28B | |
-15.96% | 15.52B | |
-41.29% | 12.17B | |
-15.50% | 12.01B | |
-11.75% | 12B | |
+7.87% | 8.87B |